Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Dashboard
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Analytics
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
Membership Levels
By The Numbers
Sanofi
32 Articles Available
1
2
Can't find what you're looking for? Try our
advanced search
.
Patent
Regeneron and Sanofi Strongly Disagree with Verdict Upholding Three of Five Amgen U.S. Patent Claims Relating to PCSK9 Antibodies
PR-M02-19-NI-059
Appointment
Sanofi CEO Olivier Brandicourt Becomes PhRMA Board Chairman
PR-M02-19-NI-007
Immuno-oncology
Regeneron and Sanofi Restructure Immuno-Oncology Collaboration for Discovery and Development Programs
PR-M01-19-NI-031
Immuno-oncology
Sanofi and Regeneron Immuno-oncology Collaboration Ending
PAO-M01-19-NI-012
New Facility
Sanofi to Consolidate Massachusetts Activities
PAO-M12-18-NI-017
Drug Development
EMA Recommends Approval of the First Oral Drug for Sleeping Sickness
PAO-M11-18-NI-019
Collaboration
Sanofi and Denali Therapeutics Enter New Collaboration
PAO-M11-18-NI-008
Vaccine
Positive Opinion Announced in EU for New Dengue Fever Vaccine
PAO-M10-18-NI-025
Approval
FDA approves Libtayo® (cemiplimab-rwlc) as first and only treatment for advanced cutaneous squamous cell carcinoma
PR-M10-18-NI-020
Market Expansion
Sanofi to further accelerate its scientific presence with the opening of a Global R&D Operations Hub in Chengdu, China
PR-M07-18-NI-017
Acquisition
Sanofi completes its acquisition of Ablynx following the expiration of the Squeeze-out Procedure
PR-M06-18-NI-074
Acquisition
Recipharm expands inhalation capabilities with GBP 45 million acquisition of Sanofi CMO business located in UK
PR-M06-18-NI-061
Extension Agreement
Beactica Signs Three-Year Extension Agreement With Sanofi
PR-M05-18-NI-114
Collaboration
Adaptive Biotechnologies Announces a Collaboration with Sanofi
PR-M05-18-NI-112
Clinical Trial
Sanofi: Accelerating Future Breakthroughs Through Clinical Trials -- Part 2 of 3
PR-M05-18-NI-080
Clinical Data
Regeneron and Sanofi Share First Positive Clinical Data for Cemiplimab in Advanced Non-small Cell Lung Cancer at ASCO
PR-M05-18-NI-075
Cell and Gene Therapy
Bioverativ and Sangamo Announce FDA Acceptance of IND Application for Gene-Edited Cell Therapy BIVV003 to Treat Sickle Cell Disease
PR-M05-18-NI-074
Announcement
Sanofi Named to DiversityInc's Top 50 Companies for Diversity®
PR-M05-18-NI-031
Diabetes
Sanofi’s Sotagliflozin Accepted for Review by EMA
PAO-M04-18-NI-006
FDA
FDA approves Toujeo® Max SoloStar®
PR-M03-18-NI-101
Innovation
Evotec and Sanofi in Exclusive Talks to Create an Evotec-Led Infectious Disease Open Innovation R&D Platform
PR-M03-18-NI-047
Licensing
Oxford BioMedica Completes Licensing Agreement with Bioverativ Inc.
PAO-M02-18-NI-019
Acquistion
Partner Therapeutics (PTx) Acquires Leukine® from Sanofi
PR-M02-18-NI-021
Acquistion
Sanofi Will Acquire Ablynx for €3.9 Billion
PAO-M01-18-NI-045
1
2
»
